No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Flublok is a recombinant influenza vaccine developed by Protein Sciences Corporation. It is the first and only FDA-approved trivalent influenza vaccine made using a novel, insect-cell-based manufacturing process. The vaccine is composed of three recombinant hemagglutinin (HA) proteins, which are produced in a baculovirus expression system. This process eliminates the need for egg-based production, which is the traditional method used to produce influenza vaccines.
Flublok is approved for use in adults aged 18 and older, and is available in the United States and Europe. It is the only influenza vaccine that is approved for use in individuals with egg allergies. The vaccine has been shown to be safe and effective in clinical trials, and is associated with a higher rate of protection against influenza compared to traditional egg-based vaccines.
The Flublok market is composed of companies that produce and distribute the vaccine. These companies include Protein Sciences Corporation, Sanofi Pasteur, GlaxoSmithKline, and Merck & Co. Show Less Read more
